

EXPERIENCE IN FORMULATING IMIQUIMOD SUPPOSITORIES FOR THE TREATMENT OF ANAL CONDYLOMATOSIS: A CASE STUDY

Muros Ortega M, Sánchez Martínez I, Valiente Borrego F, Andújar A, Sánchez Cifuentes A, Isabel
Servicio de Farmacia, Hospital De La Vega Lorenzo Guirao, Cieza, Murcia

BACKGROUND AND IMPORTANCE


Condylomata acuminata or genital warts are produced by human papillomavirus (HPV). They are considered one of the most common sexually transmitted diseases that must be treated on an individual basis. Imiquimod increases the local immune response mediated by interferon and other cytokines, it is marketed as a 5% cream for topical administration 3 times a week, a maximum of 16 weeks.

AIM AND OBJECTIVES

The aim of the study is to describe the formulation and results obtained after treatment with imiquimod suppositories manufactured by the Pharmacy Hospital Service.

MATERIALS AND METHODS

- Suppositories of imiquimod 6,25mg were prepared from Aldara® 5% cream sachets.
- Stearic mass was used as excipient to convey the active principle adding about 2,2g/suppository and molds of 2g for its preparation.
- The bain-marie was used to fusion and mixing the components.
- A sterile gauze was included to facilitate extraction if anal irritation.
- The established shelf life was 6 months between 2-8 °C.
- Suppositories were dispensed individually wrapped in aluminium foil and protected from light added a diptych of information to the patient.



RESULTS

The case of a 33 year old male, VHP 6 positive, with anal condylomatosis and high-grade epithelial dysplasia, most of which had been resected and burned previously without satisfactory results.

Imiquimod was added as an adjuvant treatment in suppositories for administration three days a week at night. Twelve suppositories were dispensed each month, the duration of treatment was 2 months.

During treatment the patient reported good tolerance, no itching, no pain in the area of administration.

One month after finish the treatment, no new macroscopic lesions were observed, nor recurrence of previous ones in anosopic examination.

CONCLUSION AND RELEVANCE

The contribution of the Pharmacy Service through the development of imiquimod suppositories has facilitated the achievement of early health results in a complex treatment pathology, allowing rectal administration through suppositories made from a specialty marketed in envelopes for topical use and reducing the duration of treatment to 8 weeks, with very good tolerance on the part of the patient.

REFERENCES AND/OR ACKNOWLEDGEMENTS

1. Bastida C et al. Formulation of imiquimod suppositories for the treatment of intra-anal neoplasms by human papillomavirus. 57th SEFH Congress.
2. PNT elaboration of the Reina Sofía General University Hospital.
3. Lacey C et al. 2012 European guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e263-70.
4. AEPCC-Guide: Condylomata acuminata. AEPCC Publications, November 2015.